Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults with HCM
Study Phase: Phase 2/Phase 3
Recruitment Status: Enrolling by invitation
Start Date: May 06, 2021
End Date: March 01, 2028
Inclusion Criteria:
- Completion of a Cytokinetics trial investigating aficamten
- LVEF ≥ 55% at the Screening Visit
Exclusion Criteria:
- Has received treatment with mavacamten: (a) within 56 days prior to dosing and (b) has not received approval for participation from the Medical Monitor.
- Has participated in another investigational device or drug study or received an investigational device or drug < 1 month (or 5 half-lives for drugs, whichever is longer) prior to screening. Other investigational procedures while participating in this study are not permitted.
- Since completion of a previous trial of aficamten has:
- Developed new-onset paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) < 30 days prior to screening. Patient may re-screen for CY 6022 after 30 days if heart rate (HR) < 100 bpm and/or rhythm is stable > 30 days
- Undergone septal reduction therapy (surgical myectomy or transcatheter alcohol ablation)
- Had a confirmed LVEF < 40% with an associated dose interruption during participation in a prior study with aficamten
- History of implantable ICD placement within 30 days prior to screening.
-
Conditions:
- Cardiomyopathies
- Cardiomyopathy, Hypertrophic
- Hypertrophy